menu
    • menu
    [{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cambridge University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cambridge University \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge University \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ambrisentan

    Menu

    Ambrisentan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Altavant Sciences

    U.S.A arrow
    Cophex
    Not Confirmed

    Altavant Sciences

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rodatristat Ethyl,Ambrisentan

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Altavant Sciences Presents Data Showing Potential For Combination Of Rodatristat Ethyl And Ambrisentan In Mode...

    Details : RVT-1201 (rodatristat ethyl) is a tryptophan hydroxylase inhibitor designed to reduce body’s peripheral production of serotonin, in preclinical study comparing rodatristat ethyl monotherapy and in combination with ambrisentan, in an animal model of PAH...

    Product Name : RVT-1201

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 05, 2022

    Lead Product(s) : Rodatristat Ethyl,Ambrisentan

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Evelo Biosciences

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Evelo Biosciences

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EDP1815,Ambrisentan,Dapagliflozin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II/ Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Evelo Biosciences announces EDP1815 to advance into phase 2/3 TACTIC-E COVID-19 trial

    Details : EDP1815 will be included in the TACTIC-E clinical trial. The trial will evaluate the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized patients...

    Product Name : EDP1815

    Product Type : Microorganism

    Upfront Cash : Inapplicable

    June 22, 2020

    Lead Product(s) : EDP1815,Ambrisentan,Dapagliflozin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Cambridge University

    Country arrow
    Cophex
    Not Confirmed

    Cambridge University

    Country arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dapagliflozin,Ambrisentan

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II/ Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cambridge Launches Fast-Turnaround Experimental Drug Trial to Treat Covid-19

    Details : The newly launched trial, known as TACTIC-E (the “E” stands for “experimental”), has been designed to test drugs that have been specifically developed to treat Covid-19 as well as investigating whether combinations of drugs that are already in us...

    Product Name : Forxiga

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 22, 2020

    Lead Product(s) : Dapagliflozin,Ambrisentan

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth